MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mirum Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$82.24+2.10 (+2.62%)
Close on Oct 19, 2026
- Market cap
- $5.21B
- P/E (TTM)
- –
- Dividend yield
- –
Mirum Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $618.07M | $569.61M | $521.31M | $471.81M | $429.10M | $379.08M | $336.41M | $306.53M | $263.96M | $218.69M | $178.87M | $75.06M | 100.0% | +44.0% |
| Livmarli | $441.15M | $400.59M | $360.01M | $317.71M | $284.60M | $243.67M | $213.30M | $190.69M | $170.28M | $155.54M | $141.80M | $75.06M | 71.4% | +55.0% |
| Bile Acid Medicines | $176.92M | $169.02M | $161.31M | $154.10M | $144.50M | $135.40M | $123.11M | $115.84M | $93.68M | $63.15M | $37.08M | – | 28.6% | +22.4% |
| License | – | – | – | – | – | – | – | – | – | – | $7.50M | $2.00M | – | – |
| License revenue | – | – | – | – | – | – | – | – | – | – | $7.50M | $2.00M | – | – |
| License and other revenue | – | – | $0 | – | – | – | – | $495.00K | $420.00K | $5.31M | $7.50M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Mirum Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.